



May 21, 2019  
JCR Pharmaceuticals Co., Ltd.

Translation

### **JCR Initiates Phase 1 Clinical Trial of JR-142, A long-acting growth hormone**

JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today the initiation of a Phase 1 clinical trial of JR-142, a recombinant long-acting growth hormone. JCR is developing JR-142 to further upgrade and enhance its growth hormone business, one of its core businesses.

JR-142 is being developed for pediatric growth hormone deficiency, and will be administered to a total of 31 healthy adult male subjects in the forthcoming trial to evaluate its safety and pharmacokinetics.

Growth hormone replacement therapy normally requires 6 to 7 self-injections a week, which invariably give rise to inconvenience, and pains on the part of the patients. To address these important issues, JCR has been focusing on research and development of a long-acting growth hormone product that can achieve sustained effects. In non-clinical evaluations, JCR’s proprietary half-life extension technology has successfully enabled a significant extension of the JR-142 half-life. It was also demonstrated that the once weekly administration of JR-142 has equivalent effects to the standard growth hormone replacement therapy.

Currently, JCR is also developing a product for short stature homeobox-containing gene (SHOX) deficiency (development code: JR-401X), as an expanded indication of its core product, GROWJECT<sup>®</sup>, a recombinant human growth hormone. (Click [here](#) for related news release.) JCR will continue striving to provide various treatment options to meet the needs of patients suffering from growth disorders.

This announcement is expected to have a minor impact on JCR’s consolidated financial results for the year ending on March 31, 2020.

#### **[About JCR Pharmaceuticals]**

JCR is a specialty pharma engaged in the research, development, manufacture and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, “Contributing towards people’s healthcare through pharmaceutical products” drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient community.

#### **[Cautionary Statement Regarding Forward-Looking Statements]**

*This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,”*

*“anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors’ pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights , an adverse court decision in a significant lawsuit and regulatory actions.*

*This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.*

*Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.*

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

[ir-info@jcrpharm.co.jp](mailto:ir-info@jcrpharm.co.jp)

END

###